Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Kymriah
Kymriah
Kymriah, Yescarta found ‘cost-effective’ in treating cancer, despite high price
Endpoints
Thu, 12/21/17 - 10:12 am
Kymriah
Yescarta
CAR-T
Novartis
Kite Pharma
Gilead Sciences
drug pricing
ASH 2017: CAR-T Wallops Blood Cancer
Motley Fool
Tue, 12/12/17 - 11:16 am
ASH2017
CAR-T
gene therapy
Novartis
Kymriah
Yescarta
Gilead Sciences
Juno Therapeutics
JCAR017
#ASH17: How does Novartis’ Kymriah DLBCL data stack up heading straight to a CAR-T showdown with Gilead?
Endpoints
Sun, 12/10/17 - 11:10 am
ASH17
Novartis
Kymriah
DLBCL
CAR-T
diffuse large B-cell lymphoma
Incoming Novartis CEO On $475,000 Cancer Therapy: 'No Question That The List Price Raises Eyebrows'
Forbes
Thu, 11/30/17 - 09:56 am
Novartis
drug pricing
cancer
Kymriah
Pharma CEOs
Vas Narasimhan
Novartis seeks European approval for cell therapy Kymriah
Reuters
Mon, 11/6/17 - 09:25 am
Novartis
Europe
CAR-T
Kymriah
diffuse large B-cell lymphoma
acute lymphoblastic leukemia
Novartis hustles along another FDA application for CAR-T star, tackling Gilead head on
Endpoints
Tue, 10/31/17 - 09:38 am
Novartis
FDA
CAR-T
Kymriah
diffuse large B-cell lymphoma
Here Come More Gene Therapies -- And More Pricing Debates
Forbes
Wed, 10/11/17 - 10:03 am
gene therapies
drug pricing
Luxturna
Spark Therapeutics
Kymriah
Novartis
Big Pharma Doesn't Want Health Outcomes To Sway Pricing -- At Least Not Yet
Forbes
Fri, 09/29/17 - 11:53 am
Big Pharma
drug pricing
gene therapy
Novartis
Kymriah
Premium price for Novartis' CAR-T sparks pushback from top PBM
BioPharma Dive
Mon, 09/25/17 - 07:23 pm
Novartis
Kymriah
CAR-T
drug pricing
Express Scripts
PBMs
Express Scripts' Miller Backs New Pricing Models for CAR-T
BioCentury
Fri, 09/22/17 - 09:13 am
Express Scripts
drug pricing
CAR-T
gene therapy
Kymriah
At $475,000, new cancer drug raises thorny questions about drug pricing — and value
Stat
Mon, 09/4/17 - 10:11 am
drug pricing
CAR-T
Novartis
Kymriah
Landmark approval won, Novartis' next test is scaling CAR-T manufacturing
BioPharma Dive
Fri, 09/1/17 - 11:24 am
Novartis
CAR-T
Kymriah
FDA
drug manufacturing
Profit on $475,000 Novartis cancer drug could be a while coming
Yahoo/Reuters
Fri, 09/1/17 - 11:15 am
Novartis
CAR-T
Kymriah
Why bluebird bio Inc Continued Its March Higher Again Today
Motley Fool
Thu, 08/31/17 - 10:13 pm
Bluebird Bio
bb2121
CAR-T
Novartis
Kymriah
Gilead Sciences
Kite Pharma
Novartis $475,000 Price Tag Sets the Stage for a Price War With Gilead Sciences
Motley Fool
Thu, 08/31/17 - 10:11 pm
Novartis
CAR-T
Kymriah
Gilead Sciences
Kite Pharma
M&A
A Cancer Doc Weighs In On CAR-T, Precision Medicine And Pricing Debates
Forbes
Thu, 08/31/17 - 09:17 am
CAR-T
precision medicine
drug pricing
Novartis
Kymriah
Novartis CEO's Dilemma: Is $475,000 Too Much For A Leukemia Breakthrough? Or Is It Not Enough?
Forbes
Wed, 08/30/17 - 11:53 pm
Novartis
CAR-T
drug pricing
FDA
acute lymphoblastic leukemia
Kymriah
Joe Jimenez
Novartis Wins Historic FDA Nod, Prices CAR-T For Leukemia at $475,000
Xconomy
Wed, 08/30/17 - 11:48 pm
Novartis
FDA
CAR-T
drug pricing
Kymriah
acute lymphoblastic leukemia
Pages
« first
‹ previous
1
2
3